ImmunityBio, Inc. (IBRX) Financial Statements
ImmunityBio financial statements at a glance
ImmunityBio reported revenue of $113.29 million for fiscal year 2025 (ended December 31, 2025), up 668.3% from fiscal year 2024. Net income was -$351.40 million, a net margin of 310.2% loss, and diluted earnings per share were -$0.38.
At the end of fiscal year 2025 it had total assets of $501.90 million, total liabilities of $1.00 billion and shareholders' equity of -$500.47 million, with cash and short-term investments of $242.82 million and total debt of $518.08 million.
Its operations brought in -$304.94 million of cash; capital spending was $4.25 million, leaving free cash flow of -$309.19 million.
The tables below show the income statement, balance sheet and cash flow statement; the key figures of the last 5 fiscal years are at the bottom of the page.
Figures from company filings, in USD; latest fiscal year ended December 31, 2025.
ImmunityBio, Inc.
Income Statement
Annual • USD
ImmunityBio key figures by fiscal year
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Revenue | $113.3M | $14.7M | $622,000 | $240,000 | $934,000 |
| Gross profit | $112.5M | $14.7M | – | – | – |
| Operating income | -$256.0M | -$344.2M | -$361.4M | -$350.6M | -$330.3M |
| Net income | -$351.4M | -$413.6M | -$583.2M | -$416.6M | -$346.8M |
| Diluted EPS | -$0.38 | -$0.62 | -$1.15 | -$1.04 | -$0.89 |
| Total assets | $501.9M | $382.9M | $504.5M | $362.4M | $468.9M |
| Total liabilities | $1.0B | $871.1M | $1.1B | $812.2M | $712.8M |
| Shareholders' equity | -$500.5M | -$489.1M | -$587.0M | -$447.3M | -$242.2M |
| Cash and short-term investments | $242.8M | $149.8M | $266.5M | $107.2M | $317.1M |
| Total debt | $518.1M | $504.2M | $726.7M | $723.8M | $645.7M |
| Operating cash flow | -$304.9M | -$391.2M | -$366.8M | -$337.5M | -$274.4M |
| Capital spending | $4.3M | $6.9M | $30.6M | $99.4M | $33.6M |
| Free cash flow | -$309.2M | -$398.1M | -$397.3M | -$436.9M | -$308.0M |
In USD. Fiscal years as reported by the company; statements on this page go back to fiscal year 2019.
Questions and answers
What was ImmunityBio's revenue in fiscal year 2025?
$113.29 million, up 668.3% from $14.75 million in fiscal year 2024.
How much profit does ImmunityBio make?
ImmunityBio reported net income of -$351.40 million for fiscal year 2025 (310.2% of revenue); operating income was -$256.03 million.
How much cash and debt does ImmunityBio have?
At the end of fiscal year 2025: cash and short-term investments of $242.82 million and total debt of $518.08 million.
What is ImmunityBio's free cash flow?
-$309.19 million in fiscal year 2025 (operating cash flow of -$304.94 million minus capital spending of $4.25 million).
